Kenan Arda1,2, Halit Irmak3, Abdurrahman Dündar4,*
1Department of Biology, Postgraduate Education Institute, Mardin Artuklu University, Mardin 47000, Turkey.
2Department of Medical Microbiology, Central Laboratory Unit, Mardin Training and Research Hospital, Mardin 47000, Turkey.
3Department of Computer Engineering, Faculty of Engineering and Architecture, Mardin Artuklu University, Mardin 47000, Turkey.
4Medical Documentation and Secretarial Program, Department of Medical Services and Techniques, Vocational School of Health Services, Mardin Artuklu University, Mardin 47000, Turkey.
*Corresponding author: Abdurrahman Dündar
References
[1] O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Re-sistance; 2016.
[2] World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.
[3] World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report. Geneva: WHO; 2025.
[4] Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15:19688.
[5] World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: WHO; 2017.
[6] Turkish Ministry of Health. National antimicrobial resistance surveillance system report. Ankara: General Directorate of Public Health; 2023.
[7] Doğanay M. Hospital infections. In: Doğanay M, Ünal S, editors. Hospital infections book. Ankara: Bilimsel Tıp Yayınevi; 2003. (Turkish)
[8] Höl Kılınç M. The most common microorganisms and resistance patterns in the adult intensive care unit of Tepecik training and research hospital [master’s thesis]. Van: Yüzüncü Yıl University; 2010. (Turkish)
[9] Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy. 2008;28:235-249.
[10] Şenol A, Balin ŞÖ. Common infections in intensive care units, gram-negative microorganisms, antibiotic resistance. KSÜ Tip Fak Derg. 2021;16:35-39. (Turkish)
[11] Versporten A, Bolokhovets G, Ghazaryan L, Abilova V, Pyshnik G, Spasojevic T, et al. Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO regional office for Europe. Lancet Infect Dis. 2014;14:381-387.
[12] İşli F, Aksoy M, Emre Aydıngöz S, Kadı E. Antibiotic prescription pattern of family physicians across Turkey: a cross-sectional analysis through the prescription information system. Turk J Fam Med Prim Care. 2020;14:87-95.
[13] WHO Regional Office for Europe. Antimicrobial medicines consumption (AMC) network: AMC data 2011–2014. Copenhagen: WHO Regional Office for Europe; 2017.
[14] Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
[15] Kirn TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect. 2013;19:513-520.
[16] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-582.
[17] Cesur S, Işık ME, Çimen SS, Aslan T, Demiröz AP, Büyükkocak Ü, et al. Antibiotic susceptibilities of Acinetobacter baumannii strains isolated from various culture samples of patients hospitalized in the intensive care unit. Ortadogu Tip Derg. 2017;9:51-55. (Turkish)
[18] Uğur M, Genç S. Three-year resistance profile of Acinetobacter baumannii and Pseudomonas aeruginosa strains isolated from intensive care units. J Turk Soc Intens Care. 2019;17:130-137. (Turkish)
[19] Kayış A, Orhan Z, Küçük B, Sur H. Acinetobacter baumannii strains isolated from various clinical samples of patients hospitalized in intensive care units and their four-year resistance profiles. Harran Üniv Tip Fak Derg. 2023;20:560-565. (Turkish)
[20] Doğanay D, Aydın M, Avşar İS. Investigation of antibiotic resistance profile of Klebsiella pneumoniae isolates isolated from dif-ferent clinical samples: one-year data during the Covid-19 pandemic. Ankara Ecz Fak Derg. 2023;47:185-195. (Turkish)
[21] Republic of Turkey Ministry of Health. National healthcare-associated infections surveillance network (USHİESA) pathogen distribution and antibiotic resistance report 2022. Ankara: T.C. Sağlık Bakanlığı; 2022. (Turkish)
[22] Coşar M, Tuncer İ, Arslan U. Antibiotic resistance profile of Pseudomonas aeruginosa strains isolated from blood cultures. Infeksiyon Derg. 2009;23:47-50. (Turkish)
[23] Yücel M, Yavuz T, Kaya D, Koçoğlu E. Monitoring the changes in antibiotic resistance rates of Pseudomonas aeruginosa isolates over the years. Ankem Derg. 2006;20:152-155. (Turkish)
[24] Güngör S, Karaayak Uzun B, Yurtsever S, Baran N. Antibiotic resistance in Staphylococcus aureus strains isolated from cultures. Ankem Derg. 2012;26:171-175. (Turkish)
[25] Ziyad MA. Investigation of antimicrobial susceptibilities and some virulence factors of coagulase negative staphylococci isolated from clinical samples [master’s thesis]. İstanbul: İstanbul University Cerrahpaşa; 2023. (Turkish)
[26] Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis. 2001;32(Suppl 2):S114-S132.
[27] Kilbas I, Ciftci IH. Antimicrobial resistance of enterococcus isolates in Turkey: a meta-analysis of current studies. J Glob Antimicrob Resist. 2018;12:26-30.
[28] Opota O, Croxatto A, Prod’hom G, Greub G. Blood culture-based diagnosis of bacteraemia: state of the art. Clin Microbiol Infect. 2015;21:313-322.